Erratum.

In the article "Denosumab Decreases Epicardial Adipose Tissue Attenuation in Dialysis Patients with Secondary Hyperparathyroidism and Low Bone Mass" [Cardiorenal Med. 2024;14(1):113-122; https://doi.org/10.1159/000535882], the authors identified an error in the labelling of Figure 2b in the originally published version.Fig. 2.Changes in serum phosphate (a) and calcium × phosphate (b) comprising denosumab and calcitriol, compared to the control group. #p < 0.05; *p < 0.01.The labels for the Denosumab group and the Control group were inadvertently interchanged. The underlying data, statistical results, and graphical elements of the figure are correct; only the group labels require reversal. The conclusions of the study remain unchanged.The authors confirmed that the incorrect label arrangement originated from an oversight during the proofchecking stage. The corrected Figure 2b, with the proper labels applied, is reproduced below.